Literature DB >> 29519691

Mortality and Readmission Following Hospitalisation for Heart Failure in Australia: A Systematic Review and Meta-Analysis.

Mohammed S Al-Omary1, Allan J Davies2, Tiffany-Jane Evans3, Bruce Bastian2, Peter J Fletcher4, John Attia1, Andrew J Boyle5.   

Abstract

BACKGROUND: Heart failure (HF) is a common, costly condition with an increasing burden on Australian health care system resources. Knowledge of the burden of HF on patients and on the health system is important for resource allocation. This study is the first systematic review to estimate the mortality and readmission rates after hospitalisation for HF in the Australian population.
METHODS: We searched for studies of HF hospitalisation in Australia published between January 1990 and May 2016, using a systematic search of PubMed, Medline, Scopus, Web of Science, EMBASE and Cochrane Library databases. Studies reporting 30-day and/or 1-year outcomes for mortality or readmission following hospitalisation were eligible and included in this study.
RESULTS: Out of 2889 articles matching the initial search criteria, a total of 13 studies representing 67,255 patients were included in the final analysis. The pooled mean age of heart failure patients was 76.3 years and 51% were male (n=34,271). The pooled estimated 30-day and 1-year all-cause mortality were 8% and 25% respectively. The pooled estimated 30-day and 1-year all-cause readmission rates were 20% and 56% respectively. There is a high prevalence of comorbidities in heart failure patients. There were limited data on readmission and mortality in rural patients and Indigenous people.
CONCLUSIONS: Heart failure hospitalisations in Australia are followed by substantial readmission and mortality rates.
Copyright © 2018 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Australia; Heart failure; Hospitalisation; Mortality; Readmission

Mesh:

Year:  2018        PMID: 29519691     DOI: 10.1016/j.hlc.2018.01.009

Source DB:  PubMed          Journal:  Heart Lung Circ        ISSN: 1443-9506            Impact factor:   2.975


  5 in total

1.  Patient characteristics, short-term and long-term outcomes after incident heart failure admissions in a regional Australian setting.

Authors:  Mohammed S Al-Omary; Tazeen Majeed; Hafssa Al-Khalil; Stuart Sugito; Mathew Clapham; Doan T M Ngo; John R Attia; Andrew J Boyle; Aaron L Sverdlov
Journal:  Open Heart       Date:  2022-05

2.  Respiratory training interventions improve health status of heart failure patients: A systematic review and network meta-analysis of randomized controlled trials.

Authors:  Mei-Hua Wang; Mei-Ling Yeh
Journal:  World J Clin Cases       Date:  2019-09-26       Impact factor: 1.337

3.  Process Evaluation of a Randomised Controlled Trial for TeleClinical Care, a Smartphone-App Based Model of Care.

Authors:  Praveen Indraratna; Uzzal Biswas; Hueiming Liu; Stephen J Redmond; Jennifer Yu; Nigel H Lovell; Sze-Yuan Ooi
Journal:  Front Med (Lausanne)       Date:  2022-02-08

4.  A Smartphone-Based Model of Care to Support Patients With Cardiac Disease Transitioning From Hospital to the Community (TeleClinical Care): Pilot Randomized Controlled Trial.

Authors:  Praveen Indraratna; Uzzal Biswas; James McVeigh; Andrew Mamo; Joseph Magdy; Dominic Vickers; Elaine Watkins; Andreas Ziegl; Hueiming Liu; Nicholas Cholerton; Joan Li; Katie Holgate; Jennifer Fildes; Robyn Gallagher; Cate Ferry; Stephen Jan; Nancy Briggs; Guenter Schreier; Stephen J Redmond; Eugene Loh; Jennifer Yu; Nigel H Lovell; Sze-Yuan Ooi
Journal:  JMIR Mhealth Uhealth       Date:  2022-02-28       Impact factor: 4.947

5.  Relationship between mutuality and depression in patients with chronic heart failure and caregivers in China: An actor-partner interdependence model analysis.

Authors:  Ting Zhou; Jiling Qu; Huiping Sun; Mengxin Xue; Yongbing Liu
Journal:  Front Psychol       Date:  2022-09-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.